The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKERO THERAPEUTICS INC COM 00973Y108 20,522 2,171,664 SH   SOLE   2,171,664 0 0
ALX ONCOLOGY HLDGS INC COM 00166B105 78,472 9,699,925 SH   SOLE   9,699,925 0 0
CINCOR PHARMA INC COM 17240Y109 40,412 2,145,035 SH   SOLE   2,145,035 0 0
ELEVATION ONCOLOGY INC COM 28623U101 2,613 1,866,339 SH   SOLE   1,866,339 0 0
HARMONY BIOSCIENCES HLDGS IN COM 413197104 70,654 1,448,720 SH   SOLE   1,448,720 0 0
IMPEL PHARMACEUTICALS INC COM 45258K109 25,721 2,759,791 SH   SOLE   2,759,791 0 0
PHARVARIS N V COM N69605108 50,862 2,301,451 SH   SOLE   2,301,451 0 0
VENTYX BIOSCIENCES INC COM 92332V107 61,291 5,011,536 SH   SOLE   5,011,536 0 0
VERONA PHARMA PLC SPONSORED ADS 925050106 678 161,897 SH   SOLE   161,897 0 0